Genetic Testing for Cardiovascular
Conditions is an essential strategy
to better understand an individual’s risk
to develop potentially debilitating heart
and cardiovascular conditions.

Learning in advance if a patient is genetically predisposed to specific cardiovascular conditions and abnormalities is an important step to improve clinical management and inform a wide range of lifestyle recommendations and interventions.

Breakthrough Genomics offers 10 targeted Cardiovascular Focus Panels including:

  • Aorta Panel (covers 53 genes)
  • Arrhythmia Panel (covers 62 genes)
  • Atrial Fibrillation Panel (covers 19 genes)
  • Brugada Syndrome Panel (covers 7 genes)
  • Cardiomyopathy Panel (covers 217 genes)
  • Congenital Structural Heart Disease Panel (covers 125 genes)
  • Dilated Cardiomyopathy (DCM) Panel (covers 130 genes)
  • Short QT Syndrome (SQTS) Panel (covers 5 genes)
  • Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT) Panel (covers 10 genes)
  • Arrhythmogenic right ventricular cardiomyopathy (ARVC) Panel (covers 21 genes)

Breakthrough Genomics’ Comprehensive
Cardiovascular Test features accurate
analysis of nearly 200 genes that can impact cardiovascular health.

This test is recommended for individuals with a family history of heart conditions of who are concerned about their long-term risk to develop heart diseases.

Benefits of genetic testing for cardiovascular conditions include:

  • informed recommendations for prevention and monitoring
  • improved clinical management decisions and treatment options
  • enhanced understanding of potential risk to family members
  • cost savings by eliminating the need for unnecessary screening
    procedures and checkups